Analysing the compliance imperatives for both US pharma and the strategic considerations for Chinese biotech navigating the cross-border environment.
Todd Liao | Morgan Lewis
Several legislative proposals, actions, and regulations are underway in parallel, all at different stages of maturity and all subject to significant political uncertainty.
For MNCs, these regulations expand scrutiny beyond foreign government actions to include commercial activities that threaten supply-chain stability.